


- 1 -

**LISTING OF CLAIMS****1-18** (CANCELED)**19** -(CURRENTLY AMENDED) A compound selected from those of formula (I) :

wherein :

p represents an integer of from 0 to 6 inclusive,

n represents an integer of from 0 to 6 inclusive,

R<sub>1</sub> and R<sub>2</sub>, which may be identical or different, each independently of the other represent a group selected from hydrogen, linear or branched (C<sub>1</sub>-C<sub>6</sub>)alkyl, aryl, and aryl-(C<sub>1</sub>-C<sub>6</sub>)alkyl in which alkyl is linear or branched,

X represents a group selected from oxygen, sulphur,

Y represents a group selected from pyridyl, and

its isomers and addition salts thereof with a pharmaceutically-acceptable acid or base,

it also being understood that :

▪ aryl denotes phenyl, biphenyl, naphthyl, dihydronaphthyl, tetrahydronaphthyl, indanyl, or indenyl, each of those groups being optionally substituted by one or more, identical or different, groups selected from halogen, linear or branched (C<sub>1</sub>-C<sub>6</sub>)alkyl, hydroxy, cyano, nitro, linear or branched (C<sub>1</sub>-C<sub>6</sub>)alkoxy, linear or branched (C<sub>2</sub>-C<sub>7</sub>)acyl, linear or branched (C<sub>1</sub>-C<sub>6</sub>)alkoxycarbonyl, linear or branched (C<sub>1</sub>-C<sub>6</sub>)trihaloalkyl, linear or branched (C<sub>1</sub>-C<sub>6</sub>)trihaloalkoxy, and amino optionally substituted by one or two linear or branched (C<sub>1</sub>-C<sub>6</sub>)alkyl,

▪ pyridyl denotes a pyridyl group which is optionally substituted by one or more, identical or different, groups selected from substituents defined hereinbefore for aryl.

**20** - (PREVIOUSLY PRESENTED) A compound of claim 19, wherein n is an integer of from 0 to 2 inclusive.

Serial No. 09/888,990  
Supplemental Response and Amendment After Notice of Appeal of May 27, 2004  
SERVIER 359

- 2 -


21- (PREVIOUSLY PRESENTED) A compound of claim 19, wherein  $R_1$  and  $R_2$ , which may be identical or different, each represent hydrogen, or linear or branched ( $C_1$ - $C_6$ )alkyl.

22- (PREVIOUSLY PRESENTED) A compound of claim 19, wherein X represents oxygen.

5 23- (CANCELED)


24- (CANCELED)

25- (PREVIOUSLY PRESENTED) A compound of claim 19, Which is a compound of formula (IA) :



10 wherein n, p, X, Y,  $R_1$  and  $R_2$  are as defined for formula (I), its isomers and addition salts thereof with a pharmaceutically-acceptable acid or base.

26- (PREVIOUSLY PRESENTED) A compound of claim 19, which is a compound of formula (IB) :



15 wherein n, p, X, Y,  $R_1$ , and  $R_2$  are as defined for formula (I), its isomers and addition salts thereof with a pharmaceutically-acceptable acid or base.

27- (PREVIOUSLY PRESENTED) A compound of claim 19, wherein p is an integer having the value 0 or 1.

28- (PREVIOUSLY PRESENTED) A compound of claim 26, wherein p represents 0, or

- 3 -

l, n represents 0, or 1, R<sub>1</sub> and R<sub>2</sub>, which may be identical or different, represent hydrogen, or linear or branched (C<sub>1</sub>-C<sub>6</sub>)alkyl, X represents oxygen, and Y represents pyridyl, its isomers and addition salts thereof with a pharmaceutically-acceptable acid or base.

- 5 29- (PREVIOUSLY PRESENTED) A compound of claim 25, wherein p represents 0, or 1, n is an integer of from 0 to 3 inclusive, R<sub>1</sub> and R<sub>2</sub>, which may be identical or different, represent hydrogen, linear or branched (C<sub>1</sub>-C<sub>6</sub>)alkyl, X represents oxygen or sulphur and Y represents pyridyl, (pyridyl being optionally substituted by a group selected from halogen, and linear or branched (C<sub>1</sub>-C<sub>6</sub>)alkyl), its isomers and addition salts thereof with a pharmaceutically-acceptable acid or base.

- 10 30- (PREVIOUSLY PRESENTED) A compound of claim 19, which is selected from :

- *N,N*-dimethyl-1-[(3-pyridyloxy)methyl]cyclopropanamine,
  - *N*-methyl-1-[(3-pyridyloxy)methyl]cyclopropanamine,
  - *N,N*-dimethyl-1-[(3-pyridylmethoxy)methyl]cyclopropanamine,
  - *N,N*-dimethyl-1-[2-(3-pyridyloxy)ethyl]cyclopropanamine,
  - 15 ▪ 1-[(3-pyridyloxy)methyl]cyclopropanamine dihydrochloride,
  - *N*-methyl-1-[[[6-methyl-3-pyridyl]oxy]methyl]cyclopropanamine hydrochloride,
  - *N*-methyl-1-[[[6-chloro-3-pyridyl]oxy]methyl]cyclopropanamine hydrochloride,
  - *N*-methyl-1-[(2-pyridylsulphonyl)methyl]cyclopropanamine dihydrochloride,
  - *N*-methyl-1-[3-(3-pyridyloxy)propyl]cyclopropanamine dihydrochloride, and
  - 20 ▪ *N*-methyl-1-[2-(3-pyridyloxy)ethyl]cyclopropanamine fumarate,
- its isomers and addition salts thereof with a pharmaceutically-acceptable acid or base.

31- (CANCELED)

32- (CANCELED)

- 25 33- (CURRENTLY AMENDED) A method for treating pain and memory or cognitive deficiency in a living animal body afflicted with age related cognitive disorders and neurodegenerative disorders selected from Fourier's Syndrome, Alzheimer's disease, Parkinson's disease, Pick's disease, Korsakoff's disease, frontal lobe and subcortical

- 4 -

dementias, ~~hyperactivity syndrome with~~ attention-deficit disorder, ~~tobacco withdrawal,~~  
~~pain, and mood disorders,~~ comprising the step of administering to the living animal body  
an amount of a compound of claim 19 which is effective for alleviation of said conditions.

- 5 34- (PREVIOUSLY PRESENTED) A pharmaceutical composition comprising as active  
principle an effective amount of a compound as claimed in claim 19, alone or in  
combination with one or more pharmaceutically-acceptable excipients or carriers.

35- (CANCELED)

36- (CANCELED)

Serial No. 09/888,990  
Supplemental Response and Amendment After Notice of Appeal of May 27, 2004  
SERVIER 359